Our Founding Team
David Pompliano, PhD.
CEO, Co-Founder , Director of Donum Therapeutics
Extensive experience in the discovery and development of anti-infective and oncology drugs within both large pharmaceutical companies and small biotechnology firms
Co-founder and CSO/CEO of Revolution Medicines (RVMD), Lodo Therapeutics , Daros, Odyssey Therapeutics
·Former Entrepreneur in Residence at Third Rock Ventures
Former VP, Global Basic Head, Infectious Diseases Franchise at Merck;
·Former VP, Head of Biology for MMPD and Infectious Diseases CEDDs at GSK
Advisory boards for ENABLE, Gates Foundation TB Drug Accelerator, Broad Institute, various NIAID- initiatives and biotech companies
BS Chemistry, UVA; PhD Chemistry, Stanford; Post-doc, Harvard (Jeremy Knowles)
Kim Lewis, PhD.
Co-Founder, Director of Donum Therapeutics
Professor of Biology; Director, Antimicrobial Discovery Center; Northeastern University
Expert in microbial drug resistance and drug discovery
PhD, Biochemistry, Moscow University
Previously faculty of MIT, University of Maryland, and Tufts University
Fellow of American Academy of Microbiology and of American Association for the Advancement of Science
Inventor in the discovery and characterization of darobactin
Phil Baran, Phd.
Co-Founder
Professor of Chemistry, Scripps Research Institute; Dr. Richard A. Lerner Endowed Chair
Expert in organic synthesis
BS, New York University, PhD, Scripps Research; Post-doc, Harvard University
Danisco Foundation Science Excellence Award, the Manchot Research Professorship Award, the Emanuel Merck Lectureship, the ACS Elias J. Corey Award, the Blavatnik National Laureate in Chemistry Award and a MacArthur Fellowship
Member National Academy of Sciences, American Academy of Arts and Sciences; Fellow of the Royal Society of Chemistry